A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants with Solid Cancers Treated with Cemiplimab

2024-515351-37-00 Protocol R5054-ONC-1843 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 7 Feb 2023 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol R5054-ONC-1843

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 40
Countries 1
Sites 1

Advanced Solid Tumor

Key facts

Sponsor
Regeneron Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
7 Feb 2023 → ongoing
Decision date (initial)
2024-09-17
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-515351-37-00
EudraCT number
2019-001604-38
ClinicalTrials.gov
NCT05259709

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumor

VersionLevelCodeTermSystem organ class
21.1 PT 10028997 Neoplasm malignant 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Regeneron Pharmaceuticals Inc.

Sponsor organisation
Regeneron Pharmaceuticals Inc.
Address
777 Old Saw Mill River Road
City
Tarrytown
Postcode
10591-6717
Country
United States

Scientific contact point

Organisation
Regeneron Pharmaceuticals Inc.
Contact name
Clinical Trial Information

Public contact point

Organisation
Regeneron Pharmaceuticals Inc.
Contact name
Clinical Trial Information

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 40 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Universitair Medisch Centrum Groningen
Medical Oncology, Hanzeplein 1, 9713 GZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2023-02-07 2023-02-07

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-30 Netherlands Acceptable with conditions
2024-09-17
2024-09-17
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-12 Netherlands Acceptable
2025-03-10
2025-03-10
3 SUBSTANTIAL MODIFICATION SM-2 2026-02-09 Netherlands Acceptable
2026-04-14
2026-05-18